Michaela Lehle

10.4k total citations · 4 hit papers
40 papers, 7.5k citations indexed

About

Michaela Lehle is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Michaela Lehle has authored 40 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 17 papers in Genetics and 13 papers in Oncology. Recurrent topics in Michaela Lehle's work include Hemophilia Treatment and Research (27 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers) and Blood Coagulation and Thrombosis Mechanisms (11 papers). Michaela Lehle is often cited by papers focused on Hemophilia Treatment and Research (27 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers) and Blood Coagulation and Thrombosis Mechanisms (11 papers). Michaela Lehle collaborates with scholars based in Switzerland, Germany and United States. Michaela Lehle's co-authors include A. Feyereislova, Eric Van Cutsem, Julie Hill, Yung‐Jue Bang, Florian Lordick, Akira Sawaki, Josef Rüschoff, Yoon‐Koo Kang, Hyun Cheol Chung and Atsushi Ohtsu and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Michaela Lehle

40 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

2010 5.3k citations Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet profile →
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

2009 596 citations Sergei Tjulandin, Michaela Lehle et al. Journal of Clinical Oncology profile →
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

2014 426 citations Eric Van Cutsem, Yung‐Jue Bang et al. Gastric Cancer profile →
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

2019 273 citations Steven W. Pipe, Midori Shima et al. The Lancet Haematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michaela Lehle Switzerland	19	4.2k	4.1k	1.7k	1.4k	1.2k	40	7.5k
Sandra Silberman United States	15	1.8k 0.4×	4.0k 1.0×	1.8k 1.0×	1.0k 0.7×	3.5k 2.8×	38	6.8k
A. Feyereislova Switzerland	19	7.9k 1.9×	7.0k 1.7×	1.8k 1.1×	2.5k 1.7×	1.2k 0.9×	31	11.3k
Petri Bono Finland	44	3.9k 0.9×	2.4k 0.6×	1.0k 0.6×	2.7k 1.9×	432 0.3×	156	7.5k
Yasushi Omuro Japan	18	4.0k 0.9×	4.0k 1.0×	1.8k 1.0×	1.3k 0.9×	1.3k 1.0×	56	6.7k
Christopher R. Garrett United States	25	2.8k 0.7×	2.4k 0.6×	953 0.6×	1.4k 1.0×	1.1k 0.9×	50	5.3k
Jonathan Polikoff United States	25	2.5k 0.6×	2.0k 0.5×	781 0.5×	694 0.5×	837 0.7×	70	4.7k
Daniel V.T. Catenacci United States	37	4.1k 1.0×	2.9k 0.7×	2.8k 1.6×	1.5k 1.1×	634 0.5×	167	6.8k
Allen Lee Cohn United States	38	4.7k 1.1×	2.4k 0.6×	875 0.5×	1.5k 1.1×	186 0.2×	159	6.9k
В. А. Горбунова Russia	24	4.5k 1.1×	5.5k 1.4×	956 0.6×	2.3k 1.6×	435 0.4×	61	7.2k
Kyoung‐Mee Kim South Korea	49	3.4k 0.8×	4.0k 1.0×	2.4k 1.4×	2.0k 1.5×	1.9k 1.6×	313	8.3k

Countries citing papers authored by Michaela Lehle

Since Specialization

Citations

This map shows the geographic impact of Michaela Lehle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaela Lehle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaela Lehle more than expected).

Fields of papers citing papers by Michaela Lehle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michaela Lehle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaela Lehle. The network helps show where Michaela Lehle may publish in the future.

Co-authorship network of co-authors of Michaela Lehle

This figure shows the co-authorship network connecting the top 25 collaborators of Michaela Lehle. A scholar is included among the top collaborators of Michaela Lehle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michaela Lehle. Michaela Lehle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahlangu, Johnny, Víctor Jiménez‐Yuste, Markus Niggli, et al.. (2024). Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Research and Practice in Thrombosis and Haemostasis. 8(2). 102364–102364. 8 indexed citations

Kiialainen, Anna, Joanne I. Adamkewicz, Claire Petry, et al.. (2023). Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Research and Practice in Thrombosis and Haemostasis. 8(1). 102306–102306. 4 indexed citations

Hermans, Cédric, Samya Obaji, Benjamin M. Beckermann, et al.. (2023). Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis. Research and Practice in Thrombosis and Haemostasis. 7(8). 102239–102239. 1 indexed citations

Négrier, Claude, Johnny Mahlangu, Michaela Lehle, et al.. (2023). Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. The Lancet Haematology. 10(3). e168–e177. 45 indexed citations

Pipe, Steven W., Peter W. Collins, Christophe Dhalluin, et al.. (2023). Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 143(14). 1355–1364. 31 indexed citations

Kiialainen, Anna, Steven W. Pipe, Karin Fijnvandraat, et al.. (2023). Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7. Blood. 142(Supplement 1). 1238–1238. 1 indexed citations

Pipe, Steven W., Miranda Minhas, Michaela Lehle, et al.. (2023). Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis. Research and Practice in Thrombosis and Haemostasis. 7(2). 100077–100077. 7 indexed citations

Callaghan, Michael U., Elina Asikanius, Michaela Lehle, et al.. (2022). Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3. Research and Practice in Thrombosis and Haemostasis. 6(6). e12782–e12782. 7 indexed citations

Skinner, Mark W., Claude Négrier, Ido Paz‐Priel, et al.. (2021). The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 27(5). 854–865. 34 indexed citations

10.

Négrier, Claude, Johnny Mahlangu, Michaela Lehle, et al.. (2021). Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study. Blood. 138(Supplement 1). 343–343. 7 indexed citations

11.

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 137(16). 2231–2242. 170 indexed citations

12.

Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood. 136(Supplement 1). 3–5. 4 indexed citations

13.

Oldenburg, Johannes, Midori Shima, Rebecca Kruse‐Jarres, et al.. (2020). Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatric Blood & Cancer. 67(10). e28474–e28474. 12 indexed citations

14.

Pipe, Steven W., Midori Shima, Michaela Lehle, et al.. (2019). Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. The Lancet Haematology. 6(6). e295–e305. 273 indexed citations breakdown →

15.

Jiménez‐Yuste, Víctor, Midori Shima, Katsuyuki Fukutake, et al.. (2017). Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4). Blood. 130(Suppl_1). 86–86. 16 indexed citations

16.

Cosson, Valérie, Vivian Ng, Michaela Lehle, & Bert L. Lum. (2014). Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemotherapy and Pharmacology. 73(4). 737–747. 87 indexed citations

17.

Cutsem, Eric Van, Yung‐Jue Bang, Feng-yi Feng, et al.. (2014). HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 18(3). 476–484. 426 indexed citations breakdown →

18.

Wynne, Chris, R. B. Ellis‐Pegler, Christian Schwabe, et al.. (2013). Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males. Cancer Chemotherapy and Pharmacology. 72(5). 1079–1087. 19 indexed citations

19.

Untch, Michael, M Muscholl, Sergei Tjulandin, et al.. (2010). First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial. Journal of Clinical Oncology. 28(9). 1473–1480. 55 indexed citations

20.

Bang, Yung‐Jue, Eric Van Cutsem, A. Feyereislova, et al.. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 376(9742). 687–697. 5261 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact